SCHEMBL10156572

SCHEMBL10156572

O=[N+]([O-])c1ccc(N2CCC(N3CCCC3)CC2)c(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
HTR7 P34969 2/20 0.47
HTT P42858 1/20 0.46
ALDH1A1 P00352 10/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
SLC6A9 P48067 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 1/20 0.44
HTR1A P08908 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4936180 0.99 GAA (0.50) GAAHTR7HTTALDH1A1LMNA
SCHEMBL10036256 0.90 WDR5 (0.49) GAAHTR7HTTALDH1A1LMNA
SCHEMBL29378218 0.87 GAA (0.61) GAAHTR7HTTALDH1A1LMNA
SCHEMBL22465912 0.87 GAA (0.61) GAAHTR7HTTALDH1A1LMNA
SCHEMBL21245661 0.84 ALDH1A1 (0.61) GAAHTTALDH1A1LMNASMN1; SMN2
SCHEMBL18688423 0.84 ALDH1A1 (0.51) GAAHTR7HTTALDH1A1LMNA
SCHEMBL1640562 0.82 ALDH1A1 (0.60) GAAHTTALDH1A1LMNASMN1; SMN2
SCHEMBL21245790 0.81 HTT (0.50) GAAHTR7HTTALDH1A1LMNA
SCHEMBL10126825 0.81 GAA (0.51) GAAHTTALDH1A1LMNASMN1; SMN2
SCHEMBL31439298 0.81 MAPT (0.52) GAAHTR7HTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
WO-2010128659-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 GAA 3821/4885HTR7 4387/4885HTT 3739/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 GAA 3821/4885HTR7 4387/4885HTT 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.